Phase II study of docetaxel alternating with cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer

Karin Mattson*, Johan Vansteenkiste, Roger Stupp, Mario Bargetzi, Antti Saarlnen, Antti Jekunen, Georges Fillet, Maria Teixeira, Ulrich Gatzemeier, Robert Olivares, Karen Soussan-Lazard, Jocelyne Bérille

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The objective of this study was to evaluate a regimen of full doses of docetaxel and cisplatin, using an alternating schedule, as first-line therapy for patients with inoperable non-small cell lung cancer (NSCLC). The standard concomitant schedule does not allow full doses of both drugs to be administered. We wanted to see if there was an advantage to be gained by administering full doses of both docetaxel and cisplatin, using a different schedule. Docetaxel 100 mg/m2 was given once every 6 weeks from week 1 and cisplatin (120 mg/m2 for two doses and 100 mg/m2 thereafter) once every 6 weeks from week 4, for six cycles (three docetaxel and three cisplatin). Thirty-six of the 44 patients enrolled were evaluable for efficacy. Forty-eight percent of the patients had good (KPS 90-100%) performance status. A median of five cycles was administered, for which no dose reductions were necessary. There were 13 of 36 partial responses (36%; 95% CI 21-54%) and 15 of 36 patients achieved stable disease (42%). The median duration of response was 10.5 months, the median time to progression was 4.5 months and the median survival was 9 months. The 1 and 2 year survival rates were 39 and 16%, respectively. The most frequent grade 3-4 toxicities were nausea (23% of patients), vomiting (18%) and neutropenia (77%). Infections were also common, but not severe. The alternating schedule produced response, toxicity and survival figures that compared favorable with those using the concomitant schedule. This study could serve as a model for future studies of non-cisplatin-containing regimens, in which full doses of docetaxel could alternate with full doses of other new agents active against NSCLC. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalAnti-Cancer Drugs
Issue number1
StatePublished - 2000


  • Alternating schedule
  • Cisplatin
  • Docetaxel
  • First-line chemotherapy
  • Non-small lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of docetaxel alternating with cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this